CAJ | 학술논문

目的：探讨厄贝沙坦联合胺碘酮治疗充血性心力衰竭合并心律失常的机制与疗效。方法选取我院2007年1月～2012年1月收治的充血性心力衰竭合并心律失常患者86例，随机分为治疗组和对照组各43例，两组均予地高辛、双克或速尿、硝酸酯、β受体阻滞剂等常规治疗，治疗组在常规治疗的基础上，予厄贝沙坦150mg/d，每日1次口服)和胺碘酮0.2g口服，每日3次，1周后改为0.2g，每日2次，2周后改为0.1～0.2g，每日1次，逐渐减至最小剂量维持治疗。疗程6个月，比较两组的疗效。结果治疗后治疗组的总有效率为明显高于对照组（P＜0.05），差异有显著性（P＜0.05）。两组患者的LVD、LVWP及HR治疗后均较治疗前明显降低，但LVEF均较治疗前明显升高，差异具有显著性；治疗后两组LVD、LVWP、LVEF、HR组间比较，观察组患者的LVD、LVWP、LVEF、HR较对照组改善更显著，组间比较差异具有显著性（P＜0.05）。结论厄贝沙坦联合胺碘酮治疗充血性心力衰竭合并心律失常可以提高临床治疗的疗效，值得推广和应用。
목적：탐토액패사탄연합알전동치료충혈성심력쇠갈합병심률실상적궤제여료효。방법선취아원2007년1월～2012년1월수치적충혈성심력쇠갈합병심률실상환자86례，수궤분위치료조화대조조각43례，량조균여지고신、쌍극혹속뇨、초산지、β수체조체제등상규치료，치료조재상규치료적기출상，여액패사탄150mg/d，매일1차구복)화알전동0.2g구복，매일3차，1주후개위0.2g，매일2차，2주후개위0.1～0.2g，매일1차，축점감지최소제량유지치료。료정6개월，비교량조적료효。결과치료후치료조적총유효솔위명현고우대조조（P＜0.05），차이유현저성（P＜0.05）。량조환자적LVD、LVWP급HR치료후균교치료전명현강저，단LVEF균교치료전명현승고，차이구유현저성；치료후량조LVD、LVWP、LVEF、HR조간비교，관찰조환자적LVD、LVWP、LVEF、HR교대조조개선경현저，조간비교차이구유현저성（P＜0.05）。결론액패사탄연합알전동치료충혈성심력쇠갈합병심률실상가이제고림상치료적료효，치득추엄화응용。
Objective To investigate irbesartan and amiodarone in patients with congestive heart failure, arrhythmia mechanisms and efficacy. Methods In our hospital,from 2007 January to 2012 January,congestive heart failure treated86patients with arrhythmia were randomly divided into treatment group and control group 43 cases, two groups were treated with digoxin, two grams or furosemide, nitrates,β-blockers and other conventional treatment group on the basis of conventional therapy, Iirbesartan 150mg/d,orally once daily) and 0.2g of oral amiodarone, 3times a day, one week later changed to 0.2 g, 2 times a day, two weeks later changed to 0.1~0.2 g, once daily, gradually reduced to the minimum dose maintenance therapy. Course of six months, compared the efficacy of the two groups.Results After treatment, the total effective rate of the treatment group was significantly higher (P <0.05), the difference was statistically significant (P <0.05). Two groups of patients LVD, LVWP and HR after treatment was significantly lower than before treatment, but significantly higher than LVEF before treatment, the difference was significant; treatment between LVD, LVWP, LVEF, HR group the two groups, the observation group patients with LVD, LVWP, LVEF, HR more significant improvement than the control group to compare the differences between the two groups was significant (P <0.05).Conclusion Irbesartan amiodarone in patients with congestive heart failure, arrhythmia can improve the efficacy of clinical treatment, should be promoted and applied.